$CRIS Cashflow Statement | Understand Stock

$CRIS

$0.45 +$0.05 (12.8%) Close

$CRIS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Non-cash lease expense
Stock-based compensation expense
Amortization of debt issuance costs
Non-cash activity related to the sale of future royalties prior to the sale of Erivedge
Gain on release of liability related to sale of future royalties associated with sale of assets
Amortization of premiums and discounts on investments
Gain on forgiveness of PPP loan
Loss on extinguishment of debt
Loss on disposal of fixed assets
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other assets
Other assets
Accounts payable and accrued and other liabilities
Operating lease liability
Total adjustments

Net cash used in operating activities
Cash flows from investing activities:
Purchases of investments
Sales and maturities of investments
Purchases of property and equipment
Proceeds from the sale of Erivedge
Net cash provided by investing activities
Cash flows from financing activities:
Proceeds from PPP Loan
Proceeds from issuance of common stock, pre-funded warrants, and common warrants, net of issuance costs
Aspire Capital Fund, LLC
Demand Sales Agreement
Total proceeds from issuance of common stock, pre-funded warrants, and common warrants, net of issuance costs

Proceeds of registered direct offering
Payments of stock issuance costs
Proceeds from royalty interest purchase agreement with Oberland Capital Management
Payment of transaction costs on royalty interest purchase agreement
Proceeds from issuance of common stock under the Company’s stock-based compensation plans
Payment of liability of future royalties, net of imputed interest
Payment on termination of credit agreement with HealthCare Royalty Partners, III, L.P.
Payments made on Curis Royalty’s debt
Net cash provided by financing activities

Net decrease in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash, beginning of period
Cash and cash equivalents and restricted cash, end of period
Supplemental cash flow data:
Issuance costs in accounts payable
Non-cash commitment shares issued to Aspire Capital
Cash paid for interest
Right-of-use assets obtained in exchange for lease liabilities
Increase in right-of-use assets and operating lease liabilities resulting from lease modification

Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash, long-term

Comments